Repository logo
 

The contribution of coding variants to the heritability of multiple cancer types using UK Biobank whole-exome sequencing data.

Accepted version
Peer-reviewed

Change log

Abstract

Genome-wide association studies have been highly successful at identifying common variants associated with cancer; however, they do not explain all the inherited risks of cancer. Family-based studies, targeted sequencing, and, more recently, exome-wide association studies have identified rare coding variants in some genes associated with cancer risk, but the overall contribution of these variants to the heritability of cancer is less clear. Here, we describe a method to estimate the genome-wide contribution of rare coding variants to heritability that fits models to the burden effect sizes using an empirical Bayesian approach. We apply this method to the burden of protein-truncating variants in over 15,000 genes for 11 cancers in the UK Biobank using whole-exome sequencing data on over 400,000 individuals. We extend the method to consider the overlap of genes contributing to pairs of cancers. We found ovarian cancer to have the greatest proportion of heritability attributable to protein-truncating variants in genes (46%). The joint cancer models highlight significant clustering of cancer types, including a near-complete overlap in susceptibility genes for breast, ovarian, prostate, and pancreatic cancer. Our results provide insights into the contribution of rare coding variants to the heritability of cancer and identify additional genes with strong evidence of susceptibility to multiple cancer types.

Description

Journal Title

Am J Hum Genet

Conference Name

Journal ISSN

0002-9297
1537-6605

Volume Title

Publisher

Elsevier

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Cancer Research UK (S_4295)
Medical Research Council (MC_UU_12015/2)
Cancer Research UK (C14478/A29329)
MRC (MC_UU_00006/2)
Cancer Research UK (SEBINT-20100002)
Cancer Research UK (PRCPJT-May21\100006)
Quality control of the UK Biobank sequencing data has been funded by the Medical Research Council (unit programs: MC_UU_12015/2, MC_UU_00006/2). The research has been conducted using the UK Biobank Resource under Application Number 28126. N.W. was supported by the International Alliance for Cancer Early Detection, an alliance between Cancer Research UK (C14478/A29329), the Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London, and the University of Manchester. J.D. was supported by core funding from the NIHR Cambridge Biomedical Research Centre (NIHR203312). X.W. and J.P.T. were supported by Cancer Research UK (PPRPGM-Nov20\100002 and PRCPJT-May21\100006).